- ChemoMetec held its Annual General Meeting on 8 October 2026, approved the 2025/26 annual report, elected PricewaterhouseCoopers as auditor, confirmed no dividend for 2025/26, and continued its existing share buyback authorisation alongside a DKK 100 million repurchase program of up to 500,000 shares.
- Alongside the decision to retain cash rather than pay a dividend, ChemoMetec raised 2026/27 revenue guidance to a range of DKK 560 to 590 million, highlighting demand for the NC-203 instrument and XcytoMatic systems as key operational drivers.
- This analysis will examine how ChemoMetec's investment narrative is reshaped by the raised 2026/27 revenue guidance, which is anchored in demand for the NC-203 and XcytoMatic platforms.
Compare how ChemoMetec’s cash retention and buyback approach stacks up against other companies by scanning our hand-picked list of solid balance sheet and fundamentals (204 results) to identify potential alternatives for your watchlist.
ChemoMetec Investment Narrative Recap
To own ChemoMetec, you need to be comfortable with a story built around NC-203 and XcytoMatic gaining wider use in cell and gene therapy workflows. The raised 2026/27 revenue range of DKK 560 to 590 million points to management seeing healthy activity in this area. The key short term catalyst remains instrument adoption and follow on consumables usage.
The biggest near term risk is that heavy spending on automation and software, and the shift toward instruments, does not translate into steady recurring revenue. The AGM decisions on no dividend and continued buybacks do not materially change that risk reward balance. They mainly adjust how existing cash is allocated.
The most relevant update for that thesis is the higher revenue guidance given on 5 October 2026. By moving the range up to DKK 560 to 590 million, ChemoMetec linked its near term outlook directly to NC-203 placements and XcytoMatic integrations with partners such as Hamilton, Tecan and Roche.
For you as an investor, that places execution risk directly on converting those collaborations and the NC 200 replacement cycle into sustainable instrument and software demand. If trials, funding or validation timelines slow, the expected contribution from these systems could arrive later than hoped and lead to a reassessment of expectations around growth spending.
ChemoMetec's story is built around analysts expecting revenues of DKK 795.3 million and earnings of DKK 351.1 million by 2029. This outlook rests on forecast annual revenue growth of 15.9% and an earnings increase of about DKK 149 million from DKK 201.8 million today.
Uncover why ChemoMetec's fair value indicates a 9% potential upside to its current price that could narrow quickly.
Exploring Other Perspectives
Four fair value estimates from the Simply Wall St Community cluster between about DKK 453 and DKK 638 per share, so some private investors see ChemoMetec as materially mispriced. Set that against raised revenue guidance, cash held back from dividends and active buybacks, and you get sharply different views. Explore those contrasting opinions directly.
Explore 3 other ChemoMetec fair value estimates, including one that suggests as much as 9% upside from the current price.
Form Your Own Verdict
Don't just follow the ticker; dig into the data and build a conviction that's truly your own.
- A great starting point for your ChemoMetec research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
- See our latest analysis for ChemoMetec. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate ChemoMetec's overall financial health at a glance.
Looking for more ChemoMetec-sized investment ideas?
If ChemoMetec has sharpened your view on quality, cash use and growth potential, use that same lens across the wider market with the Simply Wall St Screener.
- For investors hunting for resilient balance sheets and cleaner fundamentals, start with a list of solid balance sheet and fundamentals (204 results) that may fit a more conservative checklist.
- If you want potential value that still screens well on quality, scan a curated set of 174 high quality undervalued stocks that share some of the financial discipline you might look for in ChemoMetec.
- For those who care about steady income alongside fundamentals, consider a focused group of 223 dividend fortresses that combine yield with underlying business strength.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com